Phase I Study Of Ym155, Selective Survivin Suppressant In Combination With Elrotnib In Patients With Egfr-Mutant Advanced Non-Small Cell Lung Cancer.
JOURNAL OF CLINICAL ONCOLOGY(2016)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF CLINICAL ONCOLOGY(2016)